Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Calcineurin inhibitors
7 evidence topics · 6 sources
International guideline: ciclosporin for CSU unresponsive to licensed treatments, off-label
“Patients with CSU who do not show sufficient benefit from treatment with H1‐antihistamines, especially if they are also unresponsive to omalizumab, can alternatively be treated with ciclosporin 3–5 mg/kg per day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin is off‐label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using ciclosporin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“currently not licensed for CU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: ciclosporin adverse effects, embryotoxicity, and comparison with long-term corticosteroids
“but this drug cannot be recommended as standard treatment due to a higher incidence of adverse effects, especially with long‐term use” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, ciclosporin has a far better risk/benefit ratio compared to long‐term use of steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ciclosporin, although not teratogenic, is embryotoxic in animal models and is associated with preterm delivery and low birth weight in human infants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Draft joint task force guideline: calcineurin inhibitor after advanced systemic therapy
Cyclosporine meta-analysis: response rates and dose-dependent adverse events
“Eighteen studies (909 participants) including 2 randomized controlled trials were included, with 125, 363, and 266 patients with CSU receiving very low (<2 mg/kg/d), low (from 2 to< 4 mg/kg/d), and moderate (4-5 mg/kg/d) doses of CsA, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate to CsA treatment with low to moderate doses at 4, 8, and 12 weeks was 54%, 66%, and 73%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients treated with very low, low, and moderate doses of CsA, 6%, 23%, and 57% experienced 1 or more adverse event, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the limited number and quality of studies, our results should be interpreted with caution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that the appropriate dosage of CsA for CSU may range from 1 to 5 mg/kg/d, and 3 mg/kg/d is a reasonable starting dose for most patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis for the joint task force guideline: cyclosporine effective but among the most harmful
Predictors of response to cyclosporine: systematic review
“This study aimed to systemically review literature relating to factors that could potentially predict a favorable response to cyclosporine A (CsA) treatment for chronic spontaneous urticaria (CSU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 13 studies (404 patients with CSU and 200 healthy patients) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote